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People with severe mental illness (SMI) – schizophrenia, bipolar disorder and major depressive 
disorder – appear at risk for cardiovascular disease (CVD), but a comprehensive meta-analysis is 
lacking. We conducted a large-scale meta-analysis assessing the prevalence and incidence of 
CVD; coronary heart disease; stroke, transient ischemic attack or cerebrovascular disease; 
congestive heart failure; peripheral vascular disease; and CVD-related death in SMI patients 
(N=3,211,768) versus controls (N=113,383,368) (92 studies). The pooled CVD prevalence in SMI 
patients (mean age 50 years) was 9.9% (95% CI: 7.4-13.3). Adjusting for a median of seven 
confounders, patients had significantly higher odds of CVD versus controls in cross-sectional 
studies (odds ratio, OR=1.53, 95% CI: 1.27-1.83; 11 studies), and higher odds of coronary heart 
disease (OR=1.51, 95% CI: 1.47-1.55) and cerebrovascular disease (OR=1.42, 95% CI: 1.21-
1.66). People with major depressive disorder were at increased risk for coronary heart disease, 
while those with schizophrenia were at increased risk for coronary heart disease, cerebrovascular 
disease and congestive heart failure. Cumulative CVD incidence in SMI patients was 3.6% (95% 
CI: 2.7-5.3) during a median follow-up of 8.4 years (range 1.8-30.0). Adjusting for a median of six 
confounders, SMI patients had significantly higher CVD incidence than controls in longitudinal 
studies (hazard ratio, HR=1.78, 95% CI: 1.60-1.98; 31 studies). The incidence was also higher for 
coronary heart disease (HR=1.54, 95% CI: 1.30-1.82), cerebrovascular disease (HR=1.64, 95% CI: 
1.26-2.14), congestive heart failure (HR=2.10, 95% CI: 1.64-2.70), and CVD-related death 
(HR=1.85, 95% CI: 1.53-2.24). People with major depressive disorder, bipolar disorder and 
schizophrenia were all at increased risk of CVD-related death versus controls. CVD incidence 
increased with antipsychotic use (p=0.008), higher body mass index (p=0.008) and higher baseline 
CVD prevalence (p=0.03) in patients vs. controls. Moreover, CVD prevalence (p=0.007), but not 
CVD incidence (p=0.21), increased in more recently conducted studies. This large-scale meta-
analysis confirms that SMI patients have significantly increased risk of CVDs and CVD-related 
mortality, and that elevated body mass index, antipsychotic use, and CVD screening and 
management require urgent clinical attention.  
 
Key words: Cardiovascular disease, severe mental illness, schizophrenia, bipolar disorder, major 
depression, coronary heart disease, cerebrovascular disease, congestive heart failure, premature 
mortality 
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People with severe mental illness (SMI) – including schizophrenia, bipolar disorder, major 
depressive disorder, and their related spectrum disorders – have a life expectancy shortened of 
10-17.5 years compared to the general population1,2. While suicide explains some of this reduced 
life expectancy3, it is now established that physical diseases account for the overwhelming majority 
of premature mortality4,5. Among physical conditions, cardiovascular disease (CVD) is the main 
potentially avoidable contributor to early deaths in patients with SMI4. 
Given the importance of understanding the magnitude, contributors to and relative distribution 
of CVD risk in people with SMI, a number of disease-specific meta-analyses investigated if people 
with major depressive disorder, bipolar disorder or schizophrenia are at an increased risk of CVD 
compared to controls. These meta-analyses reported that people with depression (defined by the 
presence of depressive symptoms or a diagnosis of major depressive disorder) are at increased 
CVD risk6,7, including stroke (risk ratio, RR=1.34, 95% CI: 1.17-1.54), myocardial infarction (hazard 
ratio, HR=1.31, 95% CI: 1.09-1.57), coronary heart disease (RR=1.36, 95% CI: 1.24-1.49) and 
coronary heart disease-related death (HR=1.36, 95% CI: 1.14-1.63)6-8. While clearly informative,  
results concerning CVD were not specific for major depressive disorder defined according to 
established diagnostic criteria, possibly biasing such observed association towards a lower risk9. 
Another meta-analysis of longitudinal studies, which utilized standardized criteria to define bipolar 
disorder, reported mixed results, since people with that disorder were actually not at increased risk 
of myocardial infarction (RR=1.09, 95% CI: 0.96-1.24), whereas the risk of stroke was higher 
compared to controls (RR=1.74, 95% CI: 1.29-2.35)10. Among individuals with schizophrenia, 
previous meta-analyses11,12 reported an overall increased risk of CVD compared to controls 
(RR=1.53, 95% CI: 1.27-1.86). This risk increase included stroke (up to RR=1.71, 95% CI: 1.19-
2.46) and heart failure (RR=1.81, 95% CI: 1.42-2.29), but not coronary heart disease (RR=1.20, 
95% CI: 0.93-1.53). 
While the existing literature has provided relevant insights, several limitations are to be 
highlighted and important questions remain unanswered. First, some of the previous meta-
analyses did not use standardized clinical assessments to identify and categorize SMI and/or 
cardiovascular events. Second, the exact prevalence and incidence of each type of CVD among 
people with SMI, both within and across major diagnostic SMI subgroups, remains unclear. Third, 
the magnitude of premature CVD-related mortality risk in people with SMI versus controls is to be 
specified. Fourth, potential risk factors for increased CVD and related mortality risk across the SMI 
groups have not been elucidated via meta-analytic techniques, which could help identify targets for 
treatment guidelines, clinical standards and development of preventive and therapeutic programs. 
In this regard, large-scale pooled analyses in the SMI population can provide relevant information, 
allowing the investigation of potentially shared risk factors across many studies and participants, 
thus dissecting CVD risk factors associated with SMI and/or treatments for these disorders from 
factors which are non-specific or shared with the general population13. Additionally, pooling of data 
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allows for the investigation of demographic, regional and treatment variables, both within and 
across major diagnostic categories. 
Given the caveats mentioned above, the current gaps within the literature and the need to 
better understand CVD risk among people with SMI, we conducted a large scale meta-analysis 
investigating the prevalence, incidence and mortality attributed to CVD and their correlates among 
people with SMI, both within and across major diagnostic groups. 
 
 
METHODS 
 
This systematic review and meta-analysis adhered to the PRISMA statement14, following a 
predetermined, but unpublished protocol.   
 
Search strategy 
 
An electronic literature search was conducted in PubMed, Embase and Scopus from database 
inception until August 2, 2016 by two independent reviewers, using the search terms ("bipolar 
disorder" OR mania OR schizophrenia OR schizoaffective OR psychosis OR “major depression” 
OR “serious mental illness”) AND (cardiovascular OR stroke OR  cerebrovascular OR "transient 
ischemic attack" OR "transient ischaemic attack" OR “peripheral vascular” OR  "myocardial 
infarction" OR "coronary heart disease” OR” coronary artery disease” OR “ischemic heart disease” 
OR  “ischaemic heart disease” OR "hypertensive heart disease" OR  angina OR “cardiac failure” 
OR “heart failure” OR “congestive heart failure” OR  “atrial fibrillation” OR "pulmonary embolism" 
OR “cardiovascular mortality”). Furthermore, bibliographies of included papers were reviewed. 
 
Inclusion and exclusion criteria 
 
We included studies with the following characteristics: a) reporting on patients with 
schizophrenia, schizophrenia or schizoaffective disorder, bipolar disorder or bipolar spectrum 
disorders, major depressive disorder or depressive episodes, or SMI (defined as at least two 
among major depressive spectrum, bipolar spectrum and schizophrenia spectrum disorders) 
according to DSM-III, DSM-IV, DSM-5, ICD-8, ICD-9 or ICD-10, or a medical record diagnosis 
based on a clinical interview; b) having a cross-sectional or a retrospective/prospective longitudinal 
design, either with or without a control group; c) using a standardized definition of CVD; d) 
reporting RR, HR or odds ratio (OR) comparing patients with region-specific controls, percentage 
or number of events at baseline (data used for cross-sectional analysis = prevalence) and/or 
follow-up (data used for longitudinal analysis = cumulative incidence). 
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We excluded studies that investigated cardiovascular risk estimates and/or factors, subclinical 
CVD, or SMI rates in populations with CVD. In case of multiple publications from the same study, 
only the most recent paper or the article with the longest follow-up was included. When required, 
we contacted the primary/corresponding authors of potential studies to confirm eligibility or acquire 
unpublished variables of interest.   
 
Data extraction 
 
Seven authors divided in four pairs independently extracted data in a standardized Microsoft 
Excel sheet, with reciprocal validation of data extraction results. The extracted data included: 
authors, year and country; geographic region; study design; data source; period of data collection; 
SMI diagnostic criteria; CVD diagnostic criteria; specific SMI and CVD diagnosis; case and control 
inclusion criteria; number of cases and controls; percentage or number with CVD, coronary heart 
disease, cerebrovascular disease and congestive heart failure at baseline; number of events at 
follow-up; follow-up duration; number and type of covariates considered in the analyses; OR, RR, 
rate ratio and HR with their respective 95% upper and lower CIs; mean age with standard 
deviation; mean body mass index with standard deviation; proportion of males; co-occurring 
obesity, alcohol and substance related disorders, diabetes, hypertension, and hyperlipidemia; 
married status; employment status; percentage of patients with poorest income and least 
urbanized; and percentage of patients taking antipsychotics. Rate ratios calculated with Cox 
regression models were included in HR analyses. When authors did not specify whether or not a 
rate ratio had been calculated with Cox regression models, we contacted them seeking 
clarification. 
 
Outcomes 
 
Primary outcomes were CVD prevalence and cumulative incidence plus CVD-related mortality 
in people with SMI, as well as adjusted OR for prevalence and HR for incidence rates in SMI 
versus controls. Secondary outcomes were the same measures for specific CVDs (i.e., coronary 
heart disease, cerebrovascular disease, congestive heart failure) in SMI patients, as well as 
adjusted OR and HR versus controls. 
Prevalence and OR were calculated from cross-sectional studies and from baseline results of 
longitudinal studies. Where available, incidence, RR and HR were calculated from longitudinal 
studies. 
 
 
 
6 
 
Quality assessment  
 
For the purpose of this meta-analysis, a checklist (yes versus no) was used to assess the 
methodological quality of included studies. The evaluation of methodological quality across studies 
was based on the following factors: clear diagnostic criteria, presence of a control group, matching 
of the control group, covariate-adjusted outcomes, reported cardiovascular risk factors at baseline, 
and follow-up ≥5 years. 
 
Data analysis 
 
This meta-analysis was performed using Comprehensive Meta-Analysis V315. All outcomes 
were meta-analyzed when at least two studies provided data. A random effects model16,17 was 
used to account for between-study heterogeneity. We calculated pooled CVD prevalences and 
pooled CVD cumulative incidences, each with SMI subgrouping. For dichotomous primary and 
secondary outcomes comparing pooled SMI and SMI subgroups with controls, we calculated 
unadjusted as well as adjusted pooled OR for cross-sectional data, and unadjusted pooled RR, as 
well as adjusted pooled HR, for longitudinal data. Funnel plots were visually inspected, and 
Egger’s test18 and Begg-Mazumdar Kendall's tau19 were used to determine if publication bias was 
likely. When publication bias was present, the trim and fill20 procedure was run to evaluate if the 
results changed after imputing potentially missing studies.  
Between-study heterogeneity was measured using the chi-squared and I-squared statistics, 
with chi-squared p<0.05 and I-squared ≥50% indicating significant heterogeneity21. To identify 
potential moderators, meta-regression was run with Comprehensive Meta-Analysis V3 for 
unadjusted outcomes where heterogeneity was significant.  
Since CVD rates in the general population vary across the world, we also performed a 
stratified analysis across geographic regions (Asia, Europe, North America, Oceania) regarding 
raw CVD prevalence and incidence in SMI populations, and compared patients to their respective 
region-specific general population controls (calculating RRs as well as adjusted ORs and HRs for 
the four regional strata and comparing them across the different regions whenever at least two 
studies provided data per each region).  
The following study and patient characteristics were explored as potential moderators and 
mediators in addition to SMI status: geographical region of the sample; time of data collection; 
percentage of patients taking antipsychotics; and the difference between patient and control 
samples regarding age, body mass index; proportion of males and of those with married status, 
unemployed, with poorest income, least urbanized, and having co-occurring obesity, alcohol and 
substance-related disorders, diabetes, hypertension or hyperlipidemia. 
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RESULTS 
 
Search results 
 
Out of 18,064 initial hits across the searched electronic databases, 11,878 unduplicated hits 
were screened, and 11,576 were excluded through title/abstract reading. Altogether, 302 full texts 
were reviewed, and 210 were excluded with specific reasons. Among 92 studies meeting inclusion 
criteria, 27 had a cross-sectional design22-48 and 65 studies had a retrospective or prospective 
longitudinal design49-113 (Figure 1). 
 
Characteristics of included studies  
 
We included 92 studies, with a total population of 3,211,768 patients (mean age 50 years, 
49% male) with SMI and 113,383,368 controls (mean age 51 years, 49% male), with a total of 
116,595,136 subjects when summing those studies where patient and control sample sizes were 
not separately reported. Altogether, 27 studies (N=27,037,943) were cross-sectional and 65 
studies (N=89,557,193) were longitudinal. Overall, 38 studies included patients with schizophrenia 
(of which 29 were longitudinal), 30 with bipolar disorder (21 longitudinal), 30 with major depressive 
disorder (22 longitudinal), and 14 with SMI (8 longitudinal). Taken together, six studies included 
only patients with SMI (N=884,412), 16 studies included only patients with bipolar disorder 
(N=71,832), 20 studies included only patients with major depressive disorder (N=111,360), and 29 
studies included only patients with schizophrenia (N=1,591,106), while 19 studies included 
different subgroups of SMI, providing data for each of them separately (some studies included 
more than one diagnostic group, see Tables 1 and 2 for details).  
 
Meta-analysis: cross-sectional results 
 
The pooled CVD prevalence in SMI was 9.9% (95% CI: 7.4-13.3; 38 studies). Individual rates 
were 8.4% for people with bipolar disorder (95% CI: 5.4-12.6, 12 studies, N=66,911); 11.7% for 
those with major depressive disorder (95% CI: 3.6-32.2, 7 studies, N=83,965); 11.8% for those 
with schizophrenia (95% CI: 7.1-19.0, 13 studies, N=191,982), and 11.8% for those with SMI (95% 
CI: 4.1-29.4, 6 studies, N=17,286) (p<0.001 for SMI diagnostic subgroup comparisons).   
Adjusting for a median of seven potential confounders, the adjusted pooled OR for CVD in SMI 
compared to controls was 1.53 (95% CI: 1.27-1.83, p<0.001, 11 studies). For specific CVDs, 
pooled together, people with SMI had an increased risk of coronary heart disease (OR=1.51, 95% 
CI: 1.47-1.55, p<0.001, 5 studies) and cerebrovascular disease (OR=1.42, 95% CI: 1.21-1.66, 
p<0.001, 6 studies), with a strong statistical trend for congestive heart failure (OR=1.28, 95% CI: 
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0.99-1.65, p=0.06, 4 studies). Considering separately single types of SMI and CVD, in adjusted OR 
analyses, bipolar disorder was not significantly associated with CVD or its subtypes; major 
depressive disorder was significantly associated with CVD and coronary heart disease; and 
schizophrenia was significantly associated with coronary heart disease, cerebrovascular disease 
and congestive heart failure (Table 3). No adjusted ORs were available for mixed SMI groups.  
All significant results were significantly heterogeneous. After adjusting for publication bias with 
the trim-and-fill method, all pooled previously significant ORs remained statistically significant, 
confirming the association of CVD, coronary heart disease and cerebrovascular disease with SMI, 
while the OR for congestive heart failure became marginally significant (p=0.05). 
 
Meta-analysis: longitudinal adjusted results 
 
Among patients with SMI, 3.6% (95% CI: 2.7-5.3%) experienced a CVD event during a median 
follow-up period of 8.4 years (range 1.8-30.0) (65 studies). After adjusting for a median of six 
potential confounders, people with SMI were at significantly increased risk across longitudinal 
studies for CVD (HR=1.78, 95% CI: 1.60-1.98) (31 studies, N=671,384 cases vs. N=14,335,203 
controls) as well as for specific CVDs, including coronary heart disease (HR=1.54, 95% CI: 1.30-
1.82, 18 studies, N=194,017 cases vs. N=13,530,858 controls), cerebrovascular disease  
(HR=1.64, 95% CI: 1.26-2.14, 11 studies, N=188,841 cases vs. N=13,113,564 controls), 
congestive heart failure (HR=2.10, 95% CI: 1.64-2.70, 2 studies, N=409 cases vs. N=41,678 
controls), peripheral vascular disease (only unadjusted RR=3.11, 95% CI: 2.46-3.91, three 
studies), and CVD-related death (HR=1.85, 95% CI: 1.53-2.24, 16 studies, N=353,407 cases vs. 
N=7,317,053 controls). 
According to adjusted HRs, schizophrenia was significantly associated with CVD in 
longitudinal studies (HR=1.95, 95% CI: 1.41-2.70, 14 studies), as well as with coronary heart 
disease (HR=1.59, 95% CI: 1.08-2.35, 5 studies), cerebrovascular disease (HR=1.57, 95% CI: 
1.09-2.25, 5 studies), and CVD-related death (HR=2.45, 95% CI: 1.64-3.65, 9 studies). 
According to adjusted HRs, bipolar disorder was significantly associated with CVD in 
longitudinal studies (HR=1.57, 95% CI: 1.28-1.93, 10 studies) as well as with CVD-related death 
(HR=1.65, 95% CI: 1.10-2.47, 3 studies), with a trend toward a significant association with 
cerebrovascular disease (HR=1.60, 95% CI: 0.99-2.57, 4 studies), but no significant association 
with coronary heart disease (HR=1.16, 95% CI: 0.76-1.78, 4 studies). 
According to adjusted HRs, major depressive disorder was significantly associated with CVD 
in longitudinal studies (HR=1.72, 95% CI: 1.48-2.00, 18 studies) as well as with coronary heart 
disease (HR=1.63, 95% CI: 1.33-2.00, 9 studies), cerebrovascular disease (HR=2.04, 95% CI: 
1.05-3.96, 3 studies), congestive heart failure (HR=2.02, 95% CI: 1.48-2.75, 2 studies), and CVD-
related death (HR=1.63, 95% CI: 1.25-2.13, 7 studies). 
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According to adjusted HRs, mixed SMIs were significantly associated with CVD in longitudinal 
studies (HR=3.24, 95% CI: 2.15-4.88, 3 studies) as well as with CVD-related death (HR=2.75, 95% 
CI: 1.32-5.73, 3  studies). 
All significant results were significantly heterogeneous, except for mixed SMI and CVD risk, as 
well as all the congestive heart failure results. After trim and fill procedure, all results remained 
unchanged, and Egger test did not show any evidence of publication bias influencing the results 
(see Table 4 for details). 
 
Quality assessment of included studies 
 
Quality ratings of single studies are presented in Table 5. All studies used clear diagnostic 
criteria, by design. Among the 27 cross-sectional studies, all except 9 studies had a control group, 
5 studies used a matched control sample, 13 studies adjusted analyses for relevant covariates, 
and all except 6 studies reported cardiovascular risk factors. Among the 65 longitudinal studies, all 
had a control group, which was matched in all but 12 studies, only 19 studies adjusted for 
covariates, 38 studies reported on cardiovascular risk factors, and all except 12 studies had a 
follow-up of at least 5 years. 
 
Regional CVD prevalence, incidence and longitudinal risk 
 
Raw CVD prevalence and incidence rates consistently increased from Asia, through Europe 
and North America, to Oceania (Asia: 5.4% and 2.6%; Europe: 9.7% and 3.4%; North America: 
14.6% and 4.6%; Oceania: 20.6% and 26.3%; p<0.0001 for both prevalence and incidence).  
However, when comparing CVD risk in SMI patients in each region with their respective control 
groups, there was no statistically significant difference anymore across regions, with both RRs and 
adjusted HRs showing comparably increased CVD incidence risk in the SMI population (RRs 
ranging from 1.17 in Europe to 1.63 in Asia, p=0.08; and HRs ranging from 1.58 in Oceania to 1.88 
in both Europe and North America, p=0.29) (Table 6). There were insufficient numbers of studies 
to perform this analysis for adjusted ORs regarding prevalence rates across regions, or for 
adjusted ORs, RRs or HRs pertaining to specific CVD subgroups.  
 
Meta-regression 
 
Due to heterogeneous or partial reporting of possible moderator variables in the included 
studies, all meta-regression analyses were based on a much reduced number of studies. Hence, 
all analyses were less powered in comparison with the large sets of data used for cross-sectional 
prevalence and longitudinal incidence analyses. Nonetheless, CVD incidence increased 
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significantly with a higher percentage of patients using antipsychotics (12 studies; β=0.04, 95% CI: 
0.01-0.08, p=0.008), higher baseline body mass index in patients vs. controls (6 studies; β=0.24, 
95% CI: 0.06-0.42, p=0.008), and higher CVD prevalence at baseline in patients vs. controls (7 
studies; β=0.07, 95% CI: 0.01-0.14, p=0.03). CVD prevalence increased in more recent studies (38 
studies; β=0.07, 95% CI: 0.02-0.12, p=0.007), whereas the same was not true for CVD incidence 
(65 studies; β=–0.02, 95% CI=–0.07 to 0.01, p=0.21). 
 
 
DISCUSSION  
 
To our knowledge, this is the first large scale meta-analysis providing comprehensive 
quantitative data on the prevalence and incidence of CVD in people with SMI, including both 
pooled data and comparisons across CVD and SMI diagnostic subgroups. Our results establish 
that approximately 10% of people with SMI with a mean age of 50 years have at least one 
comorbid CVD. Moreover, our longitudinal analysis documents a 3.6% incidence rate of CVD 
during a median of 8.4 years of follow-up. Patients with SMI show a 53% higher risk for having 
CVD, a 78% higher risk for developing CVD, and an 85% higher risk of death from CVD compared 
to the regionally matched general population.  
This study provides a worldwide epidemiologic representation of CVD prevalence and 
incidence rates in SMI, reporting the lowest absolute prevalence and incidence in Asia, increasing 
through Europe and North America, and reaching the highest levels in Oceania. However, in 
analyses with sufficient numbers of available studies, neither RRs nor adjusted HRs indicated 
significantly different CVD incidence risk across regions, meaning that SMI patients are at an 
increased risk across the world and that CVD risk-reducing interventions in SMI are needed with 
the same urgency across all regions of the world. Moreover, while the prevalence and incidence of 
each CVD in people with SMI show some minor variations, people with major depressive disorder, 
bipolar disorder and schizophrenia are clearly all at an increased risk of CVD-related deaths 
compared to population-stratified controls, calling for urgent action.   
We were able to identify some important and actionable moderators of increased CVD risk, 
including antipsychotic use, elevated body mass index and elevated baseline CVD. Based on 
these results, it is imperative that clinicians: a) only utilize antipsychotics, particularly for non-
psychotic conditions, when alternative treatment options with lower CVD risk potential have been 
tried sufficiently; and b) screen for and manage emerging and existing CVDs as well as their risk 
factors, including weight gain and elevated body mass index. Our data, adding to research 
demonstrating a significantly higher prevalence of metabolic syndrome in people with SMI 
compared to controls114, clearly suggest there is an urgent need to prevent and manage CVD risk 
in this population.    
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Our results demonstrating a higher CVD prevalence in SMI populations versus controls in 
more recent studies are also concerning, as it supports accumulating data indicating that 
secondary prevention has been much less successful in the SMI population that in the general 
population, leading to a widening of the mortality gap in recent years49,115,116.  Our findings confirm 
prior reports that antipsychotic medication use is associated with higher CVD risk13,117,118. However, 
due to limitations in the published data, we were unable to explore variations in CVD risk profiles 
between different antipsychotic medications13,117-120. Previous research has suggested that the 
highest cardio-metabolic risks are associated with clozapine and olanzapine, whilst the lowest risk 
is with aripiprazole, ziprasidone, lurasidone, amisulpride and high potency typical 
antipsychotics13,117-122. However, in this context it is also important to note that antipsychotic 
medications can decrease CVD-related mortality, as reported for example in Finnish79 and 
Swedish123 national database studies, that are highly generalizable. These data underscore that 
symptom control and functional improvement benefit both psychiatric and overall health, as severe 
psychiatric illness negatively affects lifestyle behaviors, medical care seeking and adherence to 
medical treatments. Thus, benefits of improved psychiatric status with antipsychotics and other 
psychotropic agents need to be carefully weighed against their potential for elevated 
cardiometabolic risk, which differs across available agents13,117.   
Since antipsychotic medication use moderates CVD risk and since antipsychotics are 
increasingly used as first line treatments for much more prevalent non-psychotic conditions, 
including bipolar disorder124 and major depressive disorder with suboptimal response to 
antidepressant treatment125, the pool of people at an increased CVD risk is greatly enlarged. 
Therefore, research on the underlying mechanisms for the increased CVD risk after 
pharmacotherapy initiation is even more urgently needed to develop more effective and targeted 
preventive and interventional treatments. Studies should also examine whether different clinical 
subtypes of depression (i.e., melancholic, psychotic, atypical or undifferentiated) and bipolar 
disorder (e.g., type 1 or 2, cyclothymic disorder), certain mood states (manic, depressive, mixed or 
euthymic), or different antipsychotics, antidepressants or mood stabilizers13 significantly moderate 
CVD risk.  
Furthermore, the pathophysiology underlying the association between SMI and CVD risk is 
complex and not well understood, clearly requiring further investigation. Emerging evidence 
suggests that SMI and CVD share pathophysiological features, including hypothalamic-pituitary-
adrenal and mitochondrial dysfunction, peripheral immune activation, neuro-inflammation, oxidative 
and nitrosative stress, as well as common genetic links and epigenetic interactions126. However, 
since these different mechanisms probably interact, research that integrates these pathways is 
urgently needed. Beyond mechanistic evaluations, such studies also need to investigate the 
general and specific effects of physical health improvements on SMI outcomes.  
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Future research should also investigate optimal monitoring regimens across stratified patient 
subgroups as well as the most effective timing and efficacy of primary, secondary and tertiary 
preventive interventions120,127. In this regard, studies should comprehensively assess relevant 
moderator and mediator variables of CVD risk, including type and duration of specific psychotropic 
medications use, physical activity (including using passive monitoring via actimetry or mobile 
phone technology), diet, smoking, body mass index, personal and family history of CVD, in order to 
identify subgroups of patients who may require different monitoring and or interventions schemes. 
Long-term follow-up studies are also required to accurately document the emergence of more 
distal physical and mental health as well as health economic outcomes in relationship to the early 
identification and management of CVD risk factors and manifest CVD conditions in people with 
SMI.  
Finally, since people with SMI engage in unhealthy lifestyle and often take psychotropic 
medication for extensive periods, long-term follow-up studies are needed that assess whether 
current predictor models based on the magnitude of traditional CVD risk factor effects observed in 
the general population apply or need to be adjusted for the SMI population93, in whom CVD risk 
factors also emerge at a far earlier age117,128. 
While this is the most comprehensive meta-analysis of CVD risk in people with SMI conducted 
to date, we acknowledge several limitations that are largely related to factors in the primary data. 
First, lifestyle behavior information (e.g., physical activity) was inadequately reported, precluding 
meta-analytic assessment of these important factors as moderating or mediating variables. People 
with SMI are less likely than the general population to engage in physical activity and have higher 
levels of sedentary behaviour129, smoke more130, consume diets that are high in saturated fats and 
refined sugars, while being low in fruit and vegetables131, all factors relevant for CVD risk. Second, 
variables such as clinical subtypes of major depressive disorder and bipolar disorder, negative 
symptom severity in people with schizophrenia, and concomitant or previous use of specific 
antipsychotics, antidepressants and mood stabilizers were not reported or were insufficiently 
reported or controlled for in most available studies. Third, as expected when combining 
observational data132, many of the results were moderately to highly heterogeneous. However, in 
accordance with the MOOSE guidelines133, we conducted meta-regression analyses and were able 
to explain some of the observed heterogeneity. In addition, all of our results remained robust after 
adjustment for potential publication bias with the trim and fill analysis.  
In conclusion, SMIs pooled together were significantly associated in cross-sectional studies 
with CVD, coronary heart disease, cerebrovascular disease and CVD-related death. Additionally, in 
longitudinal studies, each specific diagnostic SMI group was significantly associated with CVD and 
CVD-related death. Furthermore, schizophrenia was associated with coronary heart disease and 
cerebrovascular disease, while bipolar disorder was associated with congestive heart failure, and 
13 
 
major depressive disorder was associated with coronary heart disease, cerebrovascular disease, 
and congestive heart failure. 
Importantly, our data confirm that CVDs are associated with an increased risk of mortality in 
people with SMI, which to a large part explains the shortened life expectancy of people with SMI 
compared to the general population2,4,5. Furthermore, we showed geographical variations in raw 
CVD prevalence and incidence risk in SMI populations, but no significant regional variance in the 
difference in CVD risk compared to the region-specific general population. Finally, the fact that 
antipsychotic use, higher body mass index and baseline CVD significantly increased the risk for 
CVD morbidity and mortality underscores the urgent need to limit antipsychotic use to those 
populations truly requiring them, choosing the lowest risk antipsychotic agents first in the treatment 
algorithm, screening all SMI patients regularly for CVD risk factors and conditions, and addressing 
any identified abnormalities aggressively.  
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Figure 1  PRISMA flow chart 
Records identified through 
database searching; 
PubMed=6,323 
Scopus=3,520 
Embase=8,221 
Total= 18,064 
Additional records identified 
through other sources 
(N=0) 
Records after duplicates removed 
(N=11,878) 
Records excluded 
(N=11,576) 
Records screened 
(N=11,878) 
Full-text articles excluded 
(N=210) 
 No data about 
cardiovascular disease (N= 
101) 
 Serious mental illness in 
cardiovascular disease 
(N=60) 
 Review article (N=35) 
 No serious mental illness 
diagnosis (N=9) 
 Same sample of another 
study (N=3) 
 Not English language (N= 
2) 
 
 
Full-text articles 
assessed for eligibility 
(N=302) 
Studies included:  
cross-sectional, N=27,  
longitudinal, N=65, 
total, N=92 
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Table 1  Cross-sectional studies: characteristics of included studies and samples 
Study Country N cases N controls 
Period of data 
collection 
SMI 
definition  
Inclusion criteria for cases 
Number of  
covariates  
Beyer et al22 USA 1,379 - 2001-2002 
Medical 
records Bipolar disorder  - 
Breese et al23 Canada 28,775 2,281,636 1995-2006 ICD-9, 10 Schizophrenia  4 
Bresee et al24 Canada 399 120,044 2005 
Medical 
records Schizophrenia 11 
Chen et al25 Taiwan 80  - 2015 DSM-IV 
Bipolar disorder,  
>60 years - 
Curkendall et 
al26 Canada 3,022 12,088 1994-1999 ICD-9 Schizophrenia 7 
Devantier et 
al27 Denmark 28 27 2009-2011 ICD-10 Major depressive disorder, late onset - 
Hagg et al28 Sweden 269  - 2000-2003 DSM-IV Schizophrenia, 20-69 years  - 
Herbst et al29 USA 
10,573 total 
population 2001-2002 DSM-IV Major depressive disorder, >60 years 11 
Huang et al30 Taiwan 117,987 21,356,304 2000-2003 ICD-9 
Bipolar disorder or major depressive 
disorder 1 
Hyde et al31 Australia 355  - 2008-2012 
Medical 
records 
Severe mental illness, prescribed 
clozapine  - 
Kilbourne et 
al32  USA 8,083  - 2001 ICD-9 Severe mental illness, >60 years  - 
Kilbourne et 
al33 USA 9,705 5,353  2000-2001 ICD-9 
Bipolar disorder or severe mental illness, 
male 3 
Lindergard34 Sweden 368 87,176 1966-1979 
ICD-9, DSM-
III 
Major depressive disorder or bipolar 
disorder  - 
Maina et al35 Italy 185  - 2006-2008 DSM-IV Severe mental illness  - 
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Study Country N cases N controls 
Period of data 
collection 
SMI 
definition  
Inclusion criteria for cases 
Number of  
covariates  
Morden et al36 Canada 65,362 65,362 2000-2007 ICD-9 Schizophrenia 4 
Munoli et al37 India 120  - 2011 ICD-10 Bipolar disorder  - 
Nielsen et al38 Denmark 937  -  1969-2014 ICD-10 Schizophrenia  - 
Niranjan et al39 USA 5,695 34,979 2007 DSM-IV Major depressive disorder 6 
Oreski et al40 Croatia 289 192 2011 ICD-10 Bipolar disorder or schizophrenia  - 
Prieto et al41 USA 988  - 2009-2013 DSM-IV Severe mental illness  - 
Scherrer et al42 USA 628 6,903 1990-1992 DSM-III Major depressive disorder, male twins  - 
Scott et al43 Multicenter 
52,095 total 
population  2001-2011 DSM-IV 
Bipolar disorder or major depressive 
disorder 6 
Shen et al44 Taiwan 203 2,036 2005-2007 ICD-9 Schizophrenia, in intensive care unit 6 
Smith et al45 UK 9,677 1,414,701 2007 
Medical 
records Schizophrenia 3 
Smith et al46 UK 2,582 1,421,796 2007 
Medical 
records Bipolar disorder 2 
Swain et al47 Multicenter 
45,288 total 
population 2001-2011 DSM-IV 
Bipolar disorder or major depressive 
disorder 7 
Zilkens et al48 Australia 656 349 2000-2009 ICD-8,9,10 
Major depressive disorder, 65-84 years, 
developing dementia  - 
 
SMI – severe mental illness 
22 
 
Table 2  Longitudinal studies: characteristics of included studies and samples 
 
Study Country N cases N controls 
Period of data 
collection 
SMI 
Definition  
Inclusion criteria for cases 
Number of 
covariates  
Almeida et al49 Australia 1,503 35,691 1996-2010 ICD-9 
Schizophrenia, bipolar disorder or major 
depressive disorder, 65-85 years, male 8 
Bremmer et al50 
The 
Netherlands 41 2,080 1992-2000 DSM-III Major depressive disorder, >55 years 13 
Butnoriene et 
al51 Lithuania 184 369  2003-2004 DSM-IV  Major depressive disorder, >45 years 4 
Callaghan et 
al52 Canada 5,999 5,999 2002-2006 
Medical 
records Bipolar disorder 6 
Callaghan et 
al53 Canada 9,815 9,815 2002-2006 ICD-10 Bipolar disorder 8 
Carney et al54 USA 1,074 726,262 1996-2001 ICD-9 Schizophrenia or schizoaffective disorder 4 
Chen et al55  Taiwan 63,913 63,913 2002-2008 ICD-9 Schizophrenia 8 
Clouse et al56 USA 16 60 1982-1992 DSM-III Major depressive disorder with diabetes 7 
Coryell et al57  USA 903  -  1998-1999 RDC Severe mental illness  - 
Crump et al58 Sweden 6,618 6,580,418 2003-2009 ICD-10 Bipolar disorder 6 
Crump et al59 Sweden 8,277 6,097,834 2003-2009 ICD-10 Schizophrenia, >25 years 6 
Davis et al60 Hawaii 280 39,000 1999-2005 
Medical 
records Major depressive disorder 5 
Davydow et al61 Denmark 681,37 5,912,158 1999-2013 ICD-9 
Schizophrenia, schizoaffective disorder or 
bipolar disorder 5 
Enger et al62 USA 1,920 9,600 1995-1999 ICD-9 
Schizophrenia, on antipsychotic 
treatment, 15-64 years - 
Fiedorowicz et 
al63  USA 288 147 1978-1981 RDC Bipolar disorder 8 
Filik et al64 UK 482 1,998 1999-2002 DSM-IV 
Schizophrenia, schizophreniform or 
schizoaffective disorder 6 
Fors et al65 Sweden 255 1,275 1981-1991 DSM-II Schizophrenia 3 
Gasse et al66 Denmark 873,898 52,693,301 1995-2009 ICD-8,10 
Severe mental illness (affective 
psychoses) 22 
Goldstein et al67  USA 5,835 26,266 2001-2005 DSM-IV 
Bipolar disorder or major depressive 
disorder 8 
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Healy et al68  UK 1,429  - 
1875-1924; 
1994-2010 
Medical 
records Schizophrenia  - 
Hendrie et al69  USA 757 30,831 1999-2008 ICD-9 Schizophrenia, >65 years - 
Hou et al70 Taiwan 8,264  - 1985-2008 
DSM-III or IV, 
ICD-9 Schizophrenia  - 
Hsieh et al71 Taiwan 9,715  - 2001-2009 ICD-9 Schizophrenia 10 
Huang et al72 Taiwan 7,937 31,748 1996-2006 ICD9 Major depressive disorder 9 
Ifteni et al73 Romania 7,189  - 1989-2011 DSM-IV Schizophrenia, inpatients  - 
Jakobsen et al74 Denmark 74,759 338,747 1977-2000 ICD-8,10 
Schizophrenia or major depressive 
disorder  2 
Janszky et al75 Sweden 646 48,675 1969-2007 ICD-8 Major depressive disorder, 18-20 years 7 
Jokinen et al76 Sweden 346  - 1980-2005 DSM-IV 
Major depressive disorder or bipolar 
disorder  - 
Joukamaa et 
al77 Finland 606 8,000 1977-1994 
Medical 
records 
Schizophrenia, mood disorder or severe 
mental illness 1 
Kendler et al78 Sweden 5,647 24,727 1998-2003 ICD-10 Major depressive disorder, twins - 
Kiviniemi et al79 Finland 6,987  - 1998-2003 ICD-9 Schizophrenia, first onset  - 
Lahti et al80 Finland 204 11,880 1969-2004 ICD-8,9,10 Schizophrenia 5 
Lan et al81 Taiwan 3,681  - 2001-2006 ICD-9  Bipolar disorder  - 
Laursen et al82 Denmark 22,294 2,411,852 1995-2007 ICD-8,10 
Schizophrenia or bipolar disorder, 15-52 
years 3 
Laursen et al83 Denmark 1,454 59,256 1995-2006 ICD-8,10 Schizophrenia or bipolar disorder 4 
Lemogne et al84   France 4,336 16,621 1990-2010 ICD-9,10 
Depression or severe mental illness 
(bipolar disorder, psychosis) 6 
Li et al85 Taiwan 1,003 4,012 1996-2009 ICD-9 Major depressive disorder 6 
Lin et al86 Taiwan 7,353 22,059 2000-2006 ICD-9 Schizophrenia 8 
Lin et al87 Taiwan 2,289 16,413 1998-2003 ICD-9 Bipolar disorder 10 
Lin et al88 Taiwan 5,001 10,002 1998-2003 ICD-9 Schizophrenia, <45 years 9 
Maina et al89 Italy 309  - 2003-2011 DSM-IV  Bipolar disorder  - 
McDermott et USA 503 2,083 1990-2003 ICD-9 Schizophrenia or severe mental illness 9 
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al90 
Murray-Thomas 
et al91  UK 232,132 193,920 1997-2001 ICD-10 
Schizophrenia, bipolar disorder or major 
depressive disorder 2 
Olfson et al92 USA 1,138,853  - 2001-2007 ICD-10 Schizophrenia, 20-64 years 4 
Osborn et al93 UK 38,824  - 1995-2010 
Medical 
records 
Bipolar disorder or severe mental illness, 
30-90 years  - 
Pratt et al94 USA 73 1107 1981-1994 DSM-III Major depressive disorder 11 
Prieto et al95 USA 334 334 1966-1996 DSM-IV Bipolar disorder 4 
Rahman et al96 Sweden 6,822 29,832 1998-2002 ICD-7,8,9,10 
Major depressive disorder, twin 
population study 7 
Ramsey et al97 USA 129 1,339 1981-1982 DSM-III 
Bipolar disorder or major depressive 
disorder 6 
Saint Onge et 
al98  USA 548 10,821 1999-2006 ICD Major depressive disorder 11 
Scherrer et al99 USA 77,568 214,749 1999-2007 ICD-9 Major depressive disorder, 25-80 years 4 
Schoepf et al100 UK 1,418 14,180 2000-2012 ICD-10 Schizophrenia, inpatients - 
Schoepf et al101  UK 621 6,210 2000-2012 ICD-10 Bipolar disorder - 
Shah et al102 USA 538 7,103 1988-2006 DSM-III 
Major depressive disorder or bipolar 
disorder, 17-39 years 14 
Stewart et al103 USA 235  - NA ICD-9 Major depressive disorder  - 
Surtees et al104 UK 3,057 16,592 1996-2008 DSM-IV Major depressive disorder, 45-80 years 11 
Ting et al105 China 153 7,682 1996-2008 DSM-IV Major depressive disorder with diabetes 18 
Torniainen et 
al106 Sweden 21,492 214,920 2006-2015 ICD-10 Schizophrenia, 17-65 years 2 
Tsai et al107 Taiwan 80,569 241,707 1999-2003 ICD-9 Schizophrenia 8 
Tsan et al108  USA 49,173  - 2002-2009 ICD-9 Schizophrenia  - 
van Marwijk et 
al109 
The 
Netherlands 143 139 2002-2003 DSM-IV Major depressive disorder, >55 years - 
Weeke et al110  Denmark 3,795  - 
1950-1957; 
1969-1977 ICD-8 Bipolar disorder  - 
Westman et 
al111 Sweden 17,101 10,631,208 1987-2006 ICD-10 Bipolar disorder 3 
Wu et al112 Taiwan 16,821 67,284 1999-2010 ICD-9 Bipolar disorder 9 
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Wu et al113  Taiwan 70,225 207,592 1996-2007 ICD-9 Schizophrenia or bipolar disorder 8 
 
SMI – severe mental illness, RDC – Research Diagnostic Criteria 
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Table 3  Meta-analysis of cross-sectional studies: unadjusted and adjusted odds ratios 
 Meta-analysis of unadjusted odds ratios Meta-analysis of covariate adjusted odds ratios 
 
N 
studies 
N participants Unadjusted odds ratios 
Hetero-
geneity 
N studies N participants 
 
Adjusted odds ratios 
 
Hetero-
geneity 
Disorder  Patients Controls OR 95% CI p I2  Patients Controls OR 95% CI p I2 
Cardiovascular disease 
Bipolar disorder 4 19,562 1,526,110 1.73 1.11 2.71 0.02 91 4 2,640 1,423,135 1.28 0.90 1.80 0.17 52 
Major depressive 
disorder 
3 1,577 47,851 2.08 1.51 2.88 <0.001 58 7 7,050 43,570 1.75 1.36 2.26 <0.001 69 
Schizophrenia 10 190,584 4,100,315 1.23 0.92 1.65 0.16 99 5 42,076 3,860,505 1.38 0.93 2.05 0.11 96 
Severe mental 
illnesses  
1 146 2,083 1.59 0.87 2.88 0.13 - - - - - - - - - 
Pooled 14 211,869 7,808,603 1.59a 1.32 1.91 <0.001 99 11 51,766 5,325,871 1.53e  1.27 1.83 <0.001 94 
Coronary heart disease 
Bipolar disorder 3 19,504 1,524,771 1.75 1.11 2.77 0.02 94 1 2,582 1,421,796 0.94 0.79 1.11 0.49 - 
Major depressive 
disorder 
1 958 35,691 2.44 2.13 2.79 <0.0001 - 3 
6,323 41,882 
2.52 1.81 3.52 <0.001 93 
Schizophrenia 8 187,359 4,086,191 1.03 0.85 1.25 0.76 98 1 399 120,044 1.52 1.48 1.56 <0.001 - 
Severe mental 
illnesses  
1 146 2,083 1.02 0.56 1.83 0.96 - - 
 - 
- - - - - 
Pooled 8 207,967 4,160,030 1.80b  1.62 2.00 <0.001 98 5 9,304 1,583,722 1.51f 1.47 1.55 <0.001 90 
Cerebrovascular disease 
Bipolar disorder 3 2,741 1,458,826 1.68 1.07 2.63 0.03 47 2 2,582 1,421,796 1.06 0.85 1.31 0.62 0 
Major depressive 
disorder 
3 1,577 47,851 2.24 1.33 3.79 0.003 81 2 
656 349 
1.64 0.96 2.78 0.07 72 
Schizophrenia 5 41,071 37,77,039 1.63 1.19 2.24 0.003 96 3 32,196 2,413,768 2.05 1.59 2.64 <0.001 61 
Severe mental 
illnesses  
1 146 2,083 1.02 0.56 1.83 0.96 - - 
- - 
- -- - - - 
Pooled 10 45,535 5,454,785 1.63c 1.31 2.02 <0.0001 93 6 35,434 3,835,913 1.42g 1.21 1.66  <0.001 90 
Congestive heart failure 
Bipolar disorder 1 2,582 1,421,796 1.38 1.03 1.84 0.03 - 1 2,582 1,421,796 1.11 0.80 1.54 0.53 0 
Major depressive 
disorder 
- - - - - - - - - 
- - 
- - - - - 
Schizophrenia 5 40,984 3,743,431 1.71 1.36 2.15 <0.001 92 3 41,474 5,708,425 1.60 1.06 2.40 0.02 97 
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Severe mental 
illnesses  
1 146 2,083 1.59 0.87 2.88 0.13 - - 
- - 
- - - - - 
Pooled 6 43,712 5,167,189 1.57d  1.32 1.87 <0.001 88 4 44,056 7,130,221 1.28h 0.99 1.65  0.06 96 
 
Bold values represent significant results 
Egger test for bias: a2.24, p=0.53; b6.41, p=0.03 (Duval & Tweedie trim-and-fill procedure adjusted OR: 1.35, 95% CI: 0.98-1.83); c1.69, p=0.24; d2.39, p=0.15; e1.73, 
p=0.18; f0.17, p=0.93; g2.59, p=0.07; h5.26, p=0.20 
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Table 4  Meta-analysis of longitudinal studies with publication bias assessment 
 
 Meta-analysis of unadjusted relative risk Meta-analysis of covariate adjusted hazard ratio 
 
N 
studies 
N participants Unadjusted relative risk 
Hetero-
geneity 
N 
studies 
N participants 
 
Adjusted hazard ratio 
 
Hetero-
geneity 
Disorder  Patients Controls RR 95% CI p I2  Patients Controls HR 95% CI p I2 
Cardiovascular disease 
Bipolar 
disorder 
12 66,549 9,606,575 1.50 1.28 1.75 <0.0001 76 10 91,187 6,967,728 1.57 1.28 1.93 <0.0001 91 
Major 
depressive 
disorder 
13 328,,431 800,718 1.29 0.92 1.81 0.14 99 18 282,621 682,045 1.72 1.48 2.00 <0.0001 67 
Schizophrenia 16 361294 16,096,125 1.21 1.006 1.45 0.04 98 14 296,778 7,176,374 1.95 1.41 2.70 <0.0001 99 
Severe mental 
illnesses  
2 874022 52,709,922 2.44 1.13 5.25 0.02 74 3 798 31,724 3.24 2.15 4.88 <0.0001 0 
Pooled 33 1,630,296 76,031,192 1.38a 1.23 1.54 <0.0001 98 31 671,384 14,335,203 1.78g 1.60 1.98 <0.0001 95 
Coronary heart disease 
Bipolar 
disorder 
4 25,286 9,200,196 1.95 1.20 3.17 0.007 96 4 19,129 6,789,683 1.16 0.76 1.78 0.49 87 
Major 
depressive 
disorder 
6 14,3671 515,187 1.15 0.71 1.85 0.57 98 9 99,028 392,210 1.63 1.33 2.00 <0.0001 80 
Schizophrenia 8 169,507 15,446,625 0.93 0.81 1.08 0.33 87 5 75,860 6,348,965 1.59 1.08 2.35 0.02 95 
Severe mental 
illnesses  
1 873,898 52,693,301 1.80 1.74 1.86 <0.0001 - - - - - - - - - 
Pooled 17 1,212,362 75,235,865 1.75b 1.69 1.80 <0.0001 99 18 194,017 13,530,858 1.54h 1.30 1.82 <0.0001 92 
Cerebrovascular disease 
Bipolar 
disorder 
6 32,898 9,082,511 1.92 1.13 3.26 0.02 97 4 23,831 6,649,375 1.60 0.99 2.57 0.05 85 
Major 
depressive 
disorder 
4 8,121 41,665 1.55 1.02 2.35 0.04 77 3 7,046 38,853 2.04 1.05 3.96 0.04 74 
Schizophrenia 8 243,254 15,475,608 1.48 1.21 1.81 <0.0001 96 5 157,964 6,425,336 1.57 1.09 2.25 0.02 95 
Severe mental 
illnesses  
- - - - - - - - - - - - - - - - 
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Pooled 17 284,273 22,187,932 1.53c 1.29 1.82 <0.0001 96 11 188,841 13,113,564 1.64i 1.26 2.14 <0.0001 90 
Congestive heart failure 
Bipolar 
disorder 
1 6,215 2,411,852 11.52 9.37 23.14 <0.0001 - 1 58 1,339 2.27 1.49 3.45 <0.0001 0 
Major 
depressive 
disorder 
- - - - - - - - 2 351 40,339 2.02 1.48 2.75 <0.0001 0 
Schizophrenia 3 85,290 9,050,272 1.80 1.15 2.79 0.009 84 - - - - - - - - 
Severe mental 
illnesses  
- - - - - - - - - - - - - - - - 
Pooled 4 91,505 11,459,059 8.24d 6.84 9.94 <0.0001 99 2 409 41,678 2.10 1.64 2.70 <0.0001 0 
Peripheral vascular disease 
Bipolar 
disorder 
1 6,215 2,411,852 3.44 2.70 4.38 <0.0001 - 
- - - - - - - - 
Major 
depressive 
disorder 
- - - - - - - - 
- - - - - - - - 
Schizophrenia 3 85,290 9,050,272 0.96 0.43 2.17 0.92 93 - - - - - - - - 
Severe mental 
illnesses  
- - - - - - - - - 
- - 
- - - - - 
Pooled 3 91,505 11,402,868 3.11e 2.46 3.91 <0.0001 98 - - - - - - - - 
Death due to cardiovascular disease 
Bipolar 
disorder 
5 37,144 356,298 1.31 0.94 1.83 0.11 75 3 17,420 162,231 1.65 1.10 2.47 0.02 88 
Major 
depressive 
disorder 
5 18,112 283,746 1.30 0.59 2.86 0.51 99 7 183,297 282,014 1.63 1.25 2.13 <0.0001 81 
Schizophrenia 9 53,779 7,179,454 1.26 0.84 1.90 0.27 96 9 152,690 6,872,808 2.45 1.64 3.65 <0.0001 96 
Severe mental 
illnesses  
3 874,146 52,714,134 2.99 2.84 3.13 <0.0001 0 3 798 31,724 2.75 1.32 5.73 0.007 75 
Pooled 18 1,151,181 60,287,400 2.89f 2.75 3.03 <0.0001 99 16 353,407 7,317,053 1.85l 1.53 2.24 <0.0001 95 
 
 
Egger test for bias: a0.44, p=0.80; b1.24, p=0.71; c0.03, p=0.96; d8.07, p=0.37; e3.08, p=0.60; f3.66, p=0.20; g1.16, p=0.31; h0.13, p=0.92; i2.57, p=0.07; l1.19, p=0.43 
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Table 5  Quality assessment of included studies 
Study  
Clear 
diagnostic 
criteria 
Control 
group 
Matched 
controls 
Coavariate 
adjusted 
analyses 
Reported 
cardiovascular 
risk factors at 
baseline 
Follow-
up at 
least 5 
years 
Cross-sectional studies 
Curkendall et al26 Y Y Y Y Y N 
Hagg et al28 Y N N N Y N 
Breese et al23 Y Y N Y Y N 
Devantier et al27 Y Y Y N Y N 
Lindergard34 Y Y N N N N 
Niranjan et al39 Y Y N Y Y N 
Scherrer et al42 Y Y N N N N 
Herbst et al29 Y Y N Y N N 
Huang et al30 Y Y N Y Y N 
Swain et al47 Y Y N Y N N 
Scott et al43 Y Y N Y N N 
Prieto et al41 Y N N N Y N 
Munoli et al37 Y N N N Y N 
Smith et al45 Y Y N Y Y N 
Maina et al35 Y N N N Y N 
Beyer et al22 Y N N N Y N 
Oreski et al40 Y Y N N Y N 
Nielsen et al38 Y N N N Y N 
Zilkens et al48 Y Y Y N N N 
Smith et al46 Y Y N Y Y N 
Kilbourne et al32 Y N N N Y N 
Hyde et al31 Y N N N Y N 
Bresee et al24 Y Y N Y Y N 
Morden et al36 Y Y Y Y Y N 
Kilbourne et al33 Y Y N Y Y N 
Chen et al25 Y N N N Y N 
Shen et al44 Y Y Y Y Y N 
Longitudinal studies 
Enger et al62 Y Y Y Y Y N 
Filik et al64 Y Y Y N Y N 
Fors et al65 Y Y Y Y N Y 
Callaghan et al52 Y Y Y Y Y N 
Lin et al86 Y Y Y Y Y Y 
Lahti et al80 Y Y Y N Y Y 
Joukamaa et al77 Y Y Y N N Y 
Lemogne et al84  Y Y Y N Y Y 
Ting et al105 Y Y Y N Y Y 
Saint Onge et al98 Y Y Y N Y Y 
Stewart et al103 Y Y N N N Y 
Coryell et al57  Y Y N N N Y 
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Study  
Clear 
diagnostic 
criteria 
Control 
group 
Matched 
controls 
Coavariate 
adjusted 
analyses 
Reported 
cardiovascular 
risk factors at 
baseline 
Follow-
up at 
least 5 
years 
Clouse et al56 Y Y Y N Y Y 
Li et al85 Y Y Y Y Y Y 
Gasse et al66 Y Y Y N N Y 
Butnoriene et al51 Y Y Y N N Y 
Bremmer et al50 Y Y Y N Y Y 
Jakobsen et al74 Y Y Y Y N Y 
Davis et al60 Y Y Y N Y N 
Jokinen et al76 Y Y N N N Y 
Kendler et al78 Y Y Y N N Y 
Shah et al102 Y Y Y N Y Y 
Surtees et al104 Y Y Y N N Y 
van Marwijk et al109 Y Y Y Y Y N 
Scherrer et al99 Y Y Y N Y Y 
Wu et al113 Y Y Y N Y Y 
Goldstein et al67 Y Y Y N Y N 
Schoepf et al100 Y Y Y Y N Y 
Almeida et al49 Y Y Y N Y Y 
Laursen et al83 Y Y Y N N Y 
Murray-Thomas et al91 Y Y Y N N N 
Crump et al58 Y Y Y N N Y 
Westman et al111 Y Y Y N N Y 
Maina et al89 Y Y N N N Y 
Weeke et al110  Y Y N N N N 
Fiedorowicz et al63 Y Y Y N Y Y 
Callaghan et al53 Y Y Y Y Y N 
Osborn et al93 Y Y Y N Y Y 
Chen et al55  Y Y Y Y Y Y 
Hou et al70 Y Y N N N Y 
Ifteni et al73 Y Y N N N Y 
Schoepf et al101 Y Y Y Y Y Y 
Hendrie et al69 Y Y Y N Y Y 
Kiviniemi et al79 Y Y N N N Y 
Crump et al59 Y Y Y N Y Y 
Wu et al112 Y Y Y Y Y Y 
Torniainen et al106 Y Y Y Y N Y 
Hsieh et al71 Y Y N N N N 
Tsan et al108 Y Y N N Y Y 
Healy et al68 Y Y N N N Y 
Prieto et al95 Y Y Y Y Y Y 
Davydow et al61 Y Y Y N N Y 
Lan et al81 Y Y N N Y Y 
Olfson et al92 Y Y N N N Y 
Tsai et al107 Y Y Y Y Y Y 
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Study  
Clear 
diagnostic 
criteria 
Control 
group 
Matched 
controls 
Coavariate 
adjusted 
analyses 
Reported 
cardiovascular 
risk factors at 
baseline 
Follow-
up at 
least 5 
years 
Ramsey et al97 Y Y Y N Y Y 
Rahman et al96 Y Y Y Y Y N 
Pratt et al94 Y Y Y N Y Y 
McDermott et al90 Y Y Y N N Y 
Lin et al88 Y Y Y Y Y Y 
Lin et al87 Y Y Y Y Y Y 
Laursen et al82 Y Y Y N N Y 
Janszky et al75 Y Y Y N Y Y 
Huang et al72 Y Y Y Y Y Y 
Carney et al54 Y Y Y N Y N 
N – no, Y – yes  
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Table 6  Prevalence and incidence of cardiovascular disease (CVD) in severe mental illness stratified by region 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Regional 
strata 
Analysis details 
Prevalence  
of CVD 
Incidence  
of CVD 
Risk ratios  
for incident  
CVD 
Adjusted hazard 
ratios for 
incident CVD 
Asia 
 
 
 
 
Europe 
 
 
 
 
North 
America 
 
 
 
Oceania 
 
 
 
 
 
 
Pooled estimate, % (95% CI) 
p value  
Heterogeneity, I2 (p value) 
N comparisons 
 
Pooled estimate, % (95% CI) 
p value  
Heterogeneity, I2 (p value) 
N comparisons 
 
Pooled estimate, % (95% CI) 
p value  
Heterogeneity, I2 (p value) 
N comparisons 
 
Pooled estimate, % (95% CI) 
p value  
Heterogeneity, I2 (p value) 
N comparisons 
 
p (difference between 
regions) 
 
5.4 (4.3-6.7) 
<0.0001 
98 (<0.0001) 
8 
 
9.7 (6.5-14.2) 
<0.0001 
97 (<0.0001) 
9 
 
14.6 (12.0-17.7) 
<0.0001 
97 (<0.0001) 
17 
 
20.6 (10.9-35.4) 
<0.0001 
97 (<0.0001) 
4 
 
<0.0001 
2.6 (1.9-3.6) 
<0.0001 
100 (<0.0001) 
12 
 
3.4 (2.2-5.3) 
<0.0001 
100 (<0.0001) 
35 
 
4.6 (3.4-6.2) 
<0.0001 
100 (<0.0001) 
15 
 
26.3 (24.1-28.6) 
<0.0001 
100 (<0.0001) 
3 
 
<0.0001 
1.63 (1.31-2.04) 
<0.0001 
99 (<0.0001) 
9 
 
1.17 (0.96-1.42) 
0.11 
97 (<0.0001) 
20 
 
1.39 (0.91-2.12) 
0.13 
97 (<0.0001) 
11 
 
1.52 (1.40-1.66) 
<0.0001 
0 (0.72) 
3 
 
0.08 
1.75 (1.38-2.22) 
<0.0001 
96 (<0.0001) 
10 
 
1.88 (1.44-2.46) 
<0.0001 
96 (<0.0001) 
22 
 
1.88 (1.62-2.19) 
<0.0001 
62 (0.003) 
11 
 
1.58 (1.41-1.78) 
<0.0001 
0 (0.84) 
3 
 
0.29 
